2023-04-28 16:00Financial Performance - The net profit attributable to shareholders for the first quarter was ¥9,613,418.44 after accounting for taxes and minority interests[6]. - The net profit attributable to shareholders of the listed company increased due to significant growth in operating income[33]. - Net profit attributable to shareholders of the listed company was ¥81,177,581.15, up 33.21% from ¥60,941,331.70 in the same period last year[41]. - The company reported a total profit of ¥112,095,668.59 for Q1 2023, compared to ¥69,806,178.33 in Q1 2022[48]. - Basic and diluted earnings per share both stood at ¥0.47, reflecting an increase driven by the growth in net profit attributable to shareholders[18][33]. - Basic earnings per share for Q1 2023 were ¥0.47, compared to ¥0.35 in the same period last year[41]. Revenue and Sales - Total operating revenue for Q1 2023 reached ¥611,252,893.65, representing a 29.06% increase compared to ¥473,617,820.88 in Q1 2022[48]. - The company experienced a significant increase in sales revenue from hyaluronic acid products due to the rapid recovery of the domestic medical beauty industry[33]. Assets and Liabilities - The total assets of the company as of March 31, 2023, amounted to ¥6,984,036,145.39, an increase from ¥6,892,398,253.88 as of December 31, 2022[12]. - The company's total assets increased by 1.33% to ¥6,984,036,145.39 compared to the end of the previous year[18]. - The total current assets increased to ¥3,660,348,521.72 from ¥3,532,115,166.92 year-over-year[12]. - The total liabilities increased to ¥1,087,042,005.92, up from ¥990,013,737.98, indicating a rise in financial obligations[18]. - The company's equity attributable to shareholders was ¥5,514,492,058.38, showing a slight decrease from the previous year's figure[18]. Cash Flow - Operating cash inflow from sales of goods and services reached ¥633,139,253.73, up from ¥511,144,187.98 in the same period last year[29]. - Net cash flow from operating activities was ¥79,930,962.49, a significant increase of 1,687.78% compared to ¥4,470,962.15 in Q1 2022[43]. - Cash flow from operating activities saw a substantial increase, attributed to the rise in operating income and previous inventory buildup[33]. - The company recorded a net cash flow from investing activities of ¥156,184,009.96, contrasting with a negative cash flow of -¥174,414,144.19 in Q1 2022[43]. Research and Development - Research and development expenses totaled ¥53,624,174.05, accounting for 8.77% of operating income, a decrease of 0.84 percentage points[18]. - Research and development expenses increased to ¥53,624,174.05 from ¥45,520,090.97, reflecting a focus on innovation[48]. Inventory and Receivables - The inventory value as of March 31, 2023, was ¥526,744,476.16, up from ¥485,238,796.88 in the previous year[12]. - The company’s accounts receivable increased to ¥415,730,029.31 from ¥381,526,389.55 year-over-year[12]. Investments - The company’s long-term equity investments decreased to ¥2,858,785.76 from ¥3,028,473.17 year-over-year[12]. - The company achieved an investment income of ¥517,071.28, down from ¥2,313,643.50 in Q1 2022[48]. Shareholder Information - The company reported a total of 8,369 ordinary shareholders at the end of the reporting period[34].